These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35963674)

  • 1. Efficacy and safety of dapagliflozin and liraglutide in patients with type 2 diabetes mellitus and newly diagnosed as overweight/obese.
    Liang YL; Chen L; Wang T; Qu JC
    Asian J Surg; 2023 Feb; 46(2):1000-1001. PubMed ID: 35963674
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China.
    Zhaohu H; Xiao H; Hailin S; Feng H
    J Diabetes Res; 2022; 2022():4126995. PubMed ID: 35990242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes.
    Tanaka K; Saisho Y; Kawai T; Tanaka M; Meguro S; Irie J; Imai T; Shigihara T; Morimoto J; Yajima K; Atsumi Y; Takei I; Itoh H
    Endocr J; 2015; 62(5):399-409. PubMed ID: 25739726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.
    Garvey WT; Birkenfeld AL; Dicker D; Mingrone G; Pedersen SD; Satylganova A; Skovgaard D; Sugimoto D; Jensen C; Mosenzon O
    Diabetes Care; 2020 May; 43(5):1085-1093. PubMed ID: 32139381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
    Li X; Wu X; Jia Y; Fu J; Zhang L; Jiang T; Liu J; Wang G
    J Diabetes Res; 2021; 2021():3715026. PubMed ID: 34660809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Dapaglifozin and Liraglutide in Patients with Poorly Controlled Type 2 Diabetes Mellitus: a 24-week, Open, Double-centered, Head to Head Trial.
    Jiang J; Lin L; Chen P
    Endocr Metab Immune Disord Drug Targets; 2021; 21(7):1366-1374. PubMed ID: 32875989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In overweight or obesity without diabetes, weekly semaglutide vs. daily liraglutide increased weight loss at 68 wk.
    Kauffman RP
    Ann Intern Med; 2022 May; 175(5):JC56. PubMed ID: 35500264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expert consensus on the use of liraglutide in the treatment of diabetes in internal medicine.
    Calvo Gómez C; Gómez-Huelgas R; Lima Ruiz J; Masmiquel Comas L; Michán Doña A; Zapatero Gaviria A
    Int J Clin Pharmacol Ther; 2016 Nov; 54(11):880-890. PubMed ID: 27487367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis.
    Konwar M; Bose D; Jaiswal SK; Maurya MK; Ravi R
    Int J Clin Pract; 2022; 2022():1201977. PubMed ID: 35936066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.
    Tanaka K; Saisho Y; Manesso E; Tanaka M; Meguro S; Irie J; Sugiura H; Kawai T; Jinzaki M; Cobelli C; Itoh H;
    Clin Drug Investig; 2015 Oct; 35(10):675-84. PubMed ID: 26369653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of GLP-1 receptor agonists on asprosin levels in normal weight or overweight/obesity patients with type 2 diabetes mellitus.
    Dai C; Zhu W
    Medicine (Baltimore); 2022 Oct; 101(43):e31334. PubMed ID: 36316938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes.
    Anholm C; Kumarathurai P; Pedersen LR; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
    Diabetes Obes Metab; 2017 Jun; 19(6):850-857. PubMed ID: 28124822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial.
    Neeland IJ; Marso SP; Ayers CR; Lewis B; Oslica R; Francis W; Rodder S; Pandey A; Joshi PH
    Lancet Diabetes Endocrinol; 2021 Sep; 9(9):595-605. PubMed ID: 34358471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study.
    Perna S; Guido D; Bologna C; Solerte SB; Guerriero F; Isu A; Rondanelli M
    Aging Clin Exp Res; 2016 Dec; 28(6):1251-1257. PubMed ID: 26749118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials.
    Ard J; Cannon A; Lewis CE; Lofton H; Vang Skjøth T; Stevenin B; Pi-Sunyer X
    Diabetes Obes Metab; 2016 Apr; 18(4):430-5. PubMed ID: 26744025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liraglutide vs. lixisenatide in obese type 2 diabetes mellitus patients: What effect should we expect in routine clinical practice?
    Moreno-Fernandez J; Garcia-Seco JA; Seco Segura AM; Garcia-Seco F; Rozas Moreno PJ; Aguirre Sanchez-Covisa M
    Prim Care Diabetes; 2020 Feb; 14(1):68-74. PubMed ID: 31171461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure-response analyses of liraglutide 3.0 mg for weight management.
    Wilding JP; Overgaard RV; Jacobsen LV; Jensen CB; le Roux CW
    Diabetes Obes Metab; 2016 May; 18(5):491-9. PubMed ID: 26833744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Clinical Efficacy of the Treatment of Overweight and Obesity in Type 2 Diabetes Mellitus by the Telemedicine Management System Based on the Internet of Things Technology.
    Lin K; Zhang W; He F; Shen J
    Comput Intell Neurosci; 2022; 2022():8149515. PubMed ID: 35785080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial.
    Oyama K; Raz I; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Park KS; Goudev A; Diaz R; Špinar J; Gause-Nilsson IAM; Mosenzon O; Sabatine MS; Wiviott SD
    Eur Heart J; 2022 Aug; 43(31):2958-2967. PubMed ID: 34427295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
    Anholm C; Kumarathurai P; Pedersen LR; Samkani A; Walzem RL; Nielsen OW; Kristiansen OP; Fenger M; Madsbad S; Sajadieh A; Haugaard SB
    Atherosclerosis; 2019 Sep; 288():60-66. PubMed ID: 31326727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.